SCHEMBL5154958

SCHEMBL5154958

CC(C)(C)c1ccc(NS(=O)(=O)c2ccc3[nH]c(C(=O)Nc4ccncc4)c(-c4ccccc4)c3c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
USP2 O75604 1/20 0.49
PKM P14618 1/20 0.49
CA1 P00915 4/20 0.48
CA2 P00918 4/20 0.48
NAMPT P43490 1/20 0.48
CA12 O43570 1/20 0.48
CA4 P22748 1/20 0.48
CA6 P23280 1/20 0.48
CA5A P35218 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
CA5B Q9Y2D0 1/20 0.48
BRD4 O60885 1/20 0.46
LMNA P02545 4/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3947425 0.95 BRD4 (0.53) ALDH1A1MEN1KMT2ASMN1; SMN2USP2
SCHEMBL3945237 0.88 KMT2A (0.58) ALDH1A1MEN1KMT2ACA1CA2
SCHEMBL3945462 0.87 ALDH1A1 (0.54) ALDH1A1MEN1KMT2ASMN1; SMN2USP2
SCHEMBL4762476 0.86 BRD4 (0.53) ALDH1A1MEN1KMT2APKMCA1
SCHEMBL3951985 0.86 BRD4 (0.55) ALDH1A1MEN1KMT2ACA1CA2
SCHEMBL3952701 0.86 ALDH1A1 (0.55) ALDH1A1MEN1KMT2ACA1CA2
SCHEMBL3943957 0.86 NAMPT (0.61) ALDH1A1MEN1KMT2ASMN1; SMN2CA1
SCHEMBL4761511 0.86 BRD4 (0.44) ALDH1A1MEN1KMT2ASMN1; SMN2USP2
SCHEMBL3947590 0.85 BRD4 (0.54) ALDH1A1MEN1KMT2ACA1CA2
SCHEMBL3946166 0.85 BRD4 (0.54) ALDH1A1MEN1KMT2ACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070259872-A1 Inhibitors of soluble adenylate cyclase BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-11-08 US claimed
US-20070259872-A1 Inhibitors of soluble adenylate cyclase BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259872-A1 Inhibitors of soluble adenylate cyclase ADCY1, ADCY2, ADCYAP1R1 ALDH1A1 235/4885MEN1 717/4885KMT2A 4523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.